KR930010559B1 - 1-히드록시알킬크산틴류, 그의 제조방법 - Google Patents

1-히드록시알킬크산틴류, 그의 제조방법 Download PDF

Info

Publication number
KR930010559B1
KR930010559B1 KR1019870011905A KR870011905A KR930010559B1 KR 930010559 B1 KR930010559 B1 KR 930010559B1 KR 1019870011905 A KR1019870011905 A KR 1019870011905A KR 870011905 A KR870011905 A KR 870011905A KR 930010559 B1 KR930010559 B1 KR 930010559B1
Authority
KR
South Korea
Prior art keywords
compound
hydroxybutyl
methylxanthine
formula
hydroxypropyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1019870011905A
Other languages
English (en)
Korean (ko)
Other versions
KR880005131A (ko
Inventor
레내 후메옥스
조르쥐 필리포시안
Original Assignee
소시에떼 데 프로듀이 네슬레 소시에떼 아노님
앙드르제이 레드지옹
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 소시에떼 데 프로듀이 네슬레 소시에떼 아노님, 앙드르제이 레드지옹 filed Critical 소시에떼 데 프로듀이 네슬레 소시에떼 아노님
Publication of KR880005131A publication Critical patent/KR880005131A/ko
Application granted granted Critical
Publication of KR930010559B1 publication Critical patent/KR930010559B1/ko
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/08—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 1 and 3, e.g. theophylline
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
KR1019870011905A 1986-10-27 1987-10-26 1-히드록시알킬크산틴류, 그의 제조방법 Expired - Fee Related KR930010559B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CH4253/86A CH670090A5 (OSRAM) 1986-10-27 1986-10-27
CH4253/86-8 1986-10-27

Publications (2)

Publication Number Publication Date
KR880005131A KR880005131A (ko) 1988-06-28
KR930010559B1 true KR930010559B1 (ko) 1993-10-28

Family

ID=4272668

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019870011905A Expired - Fee Related KR930010559B1 (ko) 1986-10-27 1987-10-26 1-히드록시알킬크산틴류, 그의 제조방법

Country Status (13)

Country Link
EP (1) EP0269841B1 (OSRAM)
JP (1) JP2527769B2 (OSRAM)
KR (1) KR930010559B1 (OSRAM)
AT (1) ATE82289T1 (OSRAM)
AU (1) AU604767B2 (OSRAM)
CA (1) CA1296001C (OSRAM)
CH (1) CH670090A5 (OSRAM)
DE (1) DE3782619T2 (OSRAM)
DK (1) DK169336B1 (OSRAM)
ES (1) ES2043631T3 (OSRAM)
GR (1) GR3006223T3 (OSRAM)
IL (1) IL84266A (OSRAM)
ZA (1) ZA877851B (OSRAM)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0570831A2 (de) * 1992-05-20 1993-11-24 Hoechst Aktiengesellschaft Verwendung von Xanthinderivaten zur Behandlung von Nervenschädigungen nach Unterbrechung der Blutzirkulation
DE4316576A1 (de) * 1993-05-18 1994-11-24 Boehringer Ingelheim Kg Verbessertes Verfahren zur Herstellung von 1,3-Dipropyl-8-(3-Oxocyclopentyl)-xanthin

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2517410A (en) * 1947-08-15 1950-08-01 Searle & Co Hydroxy alkyl xanthines and the production thereof
FR1211333A (fr) * 1955-10-19 1960-03-15 Boehringer Sohn Ingelheim Perfectionnements apportés aux procédés pour fabriquer des oxyalcoylxanthines
US4567183A (en) * 1983-03-11 1986-01-28 Analgesic Associates Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same
US4558051A (en) * 1983-10-11 1985-12-10 Richardson-Vicks, Inc. Analgesic and anti-inflammatory compositions comprising xanthines and methods of using same

Also Published As

Publication number Publication date
DK551487D0 (da) 1987-10-21
JP2527769B2 (ja) 1996-08-28
CH670090A5 (OSRAM) 1989-05-12
DK169336B1 (da) 1994-10-10
ATE82289T1 (de) 1992-11-15
AU7998087A (en) 1988-04-28
DK551487A (da) 1988-04-28
ES2043631T3 (es) 1994-01-01
EP0269841A1 (fr) 1988-06-08
EP0269841B1 (fr) 1992-11-11
JPS63122683A (ja) 1988-05-26
IL84266A (en) 1992-02-16
DE3782619T2 (de) 1993-04-22
DE3782619D1 (de) 1992-12-17
ZA877851B (en) 1988-04-22
KR880005131A (ko) 1988-06-28
IL84266A0 (en) 1988-03-31
AU604767B2 (en) 1991-01-03
CA1296001C (en) 1992-02-18
GR3006223T3 (OSRAM) 1993-06-21

Similar Documents

Publication Publication Date Title
US4289776A (en) Xanthine derivatives
US4201860A (en) Purine derivatives
US3995039A (en) Pyrazolo [1,5-a] [1,3,5] triazines
EP0045094B1 (en) Intermediates for the preparation of therapeutically active xanthine derivatives
EP0269574A2 (en) Novel adenosine derivatives and pharmaceutical compositions containing them as an active ingredient
CA2094270C (en) Xanthine derivatives
US4172829A (en) 2,9-Disubstituted adenine derivatives and their use as non-adrenergic bronchodilators
US4567254A (en) Method for preparing N6,8-disubstituted 3',5'-cyclic adenosine monophosphate and salt thereof
SK283193B6 (sk) Spôsob prípravy purínových zlúčenín a medziprodukty
US4241063A (en) Purine derivatives and their use as bronchodilators
KR930010559B1 (ko) 1-히드록시알킬크산틴류, 그의 제조방법
CA1266470A (en) Xanthine derivatives, processes for their production and their use as pharmaceuticals
US5648489A (en) Syntheses of acyclic guanine nucleosides
PL75064B1 (OSRAM)
JPS634544B2 (OSRAM)
Schaeffer et al. Synthesis of Potential Anticancer Agents. XVII. Preparation of 9-(Substituted-cycloaliphatic)-purines2
US4575553A (en) Antitumor m-AMSA analog
US3029239A (en) Basic substituted 1-and 7-alkylxanthines or salts thereof
CA1086316A (en) Purine acyclic nucleosides
US5338741A (en) 1-hydroxyalkylxanthines and medicaments containing them
PT87705B (pt) Processo para a preparacao de derivados de 6-desoxi-guanina
US4277603A (en) Preparation of 5-deazariboflavins
EP0378706B1 (en) 5-substituted uridine derivatives and intermediates for their preparation
US4587052A (en) 1H-pyrrolo-[2,1-C][1,4]benzodiazepine-2-acrylamide compounds having antitumor activity
US5756735A (en) Xanthine derivatives

Legal Events

Date Code Title Description
PA0109 Patent application

St.27 status event code: A-0-1-A10-A12-nap-PA0109

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

A201 Request for examination
PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

J2X1 Appeal (before the patent court)

Free format text: APPEAL AGAINST DECISION TO DECLINE REFUSAL

G160 Decision to publish patent application
PG1605 Publication of application before grant of patent

St.27 status event code: A-2-2-Q10-Q13-nap-PG1605

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U11-oth-PR1002

Fee payment year number: 1

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

FPAY Annual fee payment

Payment date: 19970830

Year of fee payment: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

LAPS Lapse due to unpaid annual fee
PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 19981029

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 19981029

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PN2301 Change of applicant

St.27 status event code: A-5-5-R10-R13-asn-PN2301

St.27 status event code: A-5-5-R10-R11-asn-PN2301

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000